» Articles » PMID: 1958444

The Influence of Co-administered Organic Acids on the Kinetics and Dynamics of Frusemide

Overview
Specialty Pharmacology
Date 1991 Oct 1
PMID 1958444
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

1. This study examines the effects of pretreatment with probenecid with and without pyrazinamide on the elimination kinetics and diuretic action of frusemide. 2. Six normal male volunteers received 40 mg frusemide i.v. on three occasions; i.e. once on its own and twice after pretreatment with 2 g probenecid with and without 3 g pyrazinamide. Both these latter drugs were administered orally 3 h before frusemide administration thereby attempting optimal suppression of proximal tubular secretion. Urinary losses were replaced i.v. with isovolumetric amounts of normal saline while insensible losses were compensated for by taking tap water orally. 3. The mean cumulative urinary frusemide excretion was significantly and similarly decreased by pretreatment with probenecid (34.9%) and probenecid plus pyrazinamide (33.6%), but the mean total volume of diuresis and the mean cumulative urinary sodium excretion did not differ significantly between treatments over the 5 h period. 4. The diuretic efficiency of frusemide was significantly increased with probenecid pretreatment during the first 90 min period after frusemide administration. Furthermore, in the first 30 min after administration the percent sodium fractional excretion was higher after pretreatment with probenecid even though the mean frusemide excretion rate was more than three times with frusemide alone than with probenecid-frusemide (374.4 micrograms min-1 vs 119.1 micrograms min-1). Pretreatment with probenecid results in a higher concentration on the peritubular or blood side of the tubules and these results lead us to question the unconditional acceptance of a luminal site of action for the loop diuretics. Alternatively, probenecid may act in some other way to increase the effects of frusemide.

Citing Articles

Renal drug transporters and their significance in drug-drug interactions.

Yin J, Wang J Acta Pharm Sin B. 2016; 6(5):363-373.

PMID: 27709005 PMC: 5045553. DOI: 10.1016/j.apsb.2016.07.013.


The efficiency concept in pharmacodynamics.

Alvan G, Paintaud G, Wakelkamp M Clin Pharmacokinet. 1999; 36(5):375-89.

PMID: 10384860 DOI: 10.2165/00003088-199936050-00005.


The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit.

Pichette V, Geadah D, du Souich P Br J Pharmacol. 1996; 119(5):885-90.

PMID: 8922736 PMC: 1915948. DOI: 10.1111/j.1476-5381.1996.tb15755.x.


Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency.

van Olden R, van Meyel J, Gerlag P Eur J Clin Pharmacol. 1995; 47(6):483-8.

PMID: 7768248 DOI: 10.1007/BF00193698.


Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect.

Alvan G, Paintaud G, Eckernas S, Grahnen A Br J Clin Pharmacol. 1992; 34(1):47-52.

PMID: 1633067 PMC: 1381374. DOI: 10.1111/j.1365-2125.1992.tb04106.x.

References
1.
Holland S, WILLIAMSON H . Probenecid inhibition of bumetanide-induced natriuresis in the dog. Proc Soc Exp Biol Med. 1979; 161(3):299-302. DOI: 10.3181/00379727-161-40540. View

2.
Brater D . Effects of probenecid on furosemide response. Clin Pharmacol Ther. 1978; 24(5):548-54. DOI: 10.1002/cpt1978245548. View

3.
Holford N, Sheiner L . Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981; 6(6):429-53. DOI: 10.2165/00003088-198106060-00002. View

4.
Kaojarern S, Day B, Brater D . The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int. 1982; 22(1):69-74. DOI: 10.1038/ki.1982.134. View

5.
Brater D . Pharmacodynamic considerations in the use of diuretics. Annu Rev Pharmacol Toxicol. 1983; 23:45-62. DOI: 10.1146/annurev.pa.23.040183.000401. View